Health and Healthcare

Health and Healthcare Articles

All Health and Healthcare Articles

5864 Articles

Chris Lange | Apr 10, 2018 at 9:50 AM EDT

Selecta Biosciences Sinks Despite Positive Midstage Data

Selecta Biosciences saw its shares sink on Tuesday after the company presented new data from patients receiving SEL-212 for the…

Chris Lange | Apr 10, 2018 at 9:45 AM EDT

Why Spectrum Pharmaceuticals Is Climbing

Spectrum Pharmaceuticals saw its shares make a handy gain early on Tuesday after the firm provided an update on its…

Jon C. Ogg | Apr 9, 2018 at 4:35 PM EDT

Why Analysts See Pacira Pharma in a Night and Day Contrast

Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) has found itself in the middle of a great opportunity but not being able to…

Chris Lange | Apr 9, 2018 at 11:20 AM EDT

Surface Oncology Announces Potential Pricing for IPO

Surface Oncology intends to price 6 million shares to result in an initial public offering valued up to more than…

Chris Lange | Apr 9, 2018 at 10:25 AM EDT

Therapix Takes a Big Step Forward With Its Cannabinoid Platform

Therapix Biosciences shares made a solid gain to start the week after it announced topline results for its cannabinoid product…

Chris Lange | Apr 9, 2018 at 10:05 AM EDT

Merck Moves Ahead With Late-Stage Trial Win

Shares of Merck had a boost early Monday after the firm announced that its Phase 3 trial of Keytruda for…

Chris Lange | Apr 9, 2018 at 8:50 AM EDT

Why Menlo Therapeutics Shares Were Halved

Menlo Therapeutics shares were slaughtered early on Monday after the firm issued an update for its midstage clinical trial for…

Paul Ausick | Apr 9, 2018 at 8:25 AM EDT

Novartis Gambles $8.7 Billion on Gene-Therapy Firm

Swiss drug maker Novartis has agreed to acquire U.S.-based AveXis for $8.7 billion in cash. AveXis is developing a gene-therapy…

Lee Jackson | Apr 7, 2018 at 9:05 AM EDT

These 5 Stocks Could Be in Big Trouble If Interest Rates Go Higher

If interest rates continue higher, these five health care companies with floating rate debt could face some major issues.

Chris Lange | Apr 6, 2018 at 10:05 AM EDT

What Has Tanked Incyte and NewLink Genetics

Incyte saw its shares make a sharp left turn on Friday after the firm gave an update on its late-stage…

Paul Ausick | Apr 5, 2018 at 12:10 PM EDT

What the Opioid Epidemic Costs Employers

The opioid epidemic in the U.S. cost employers $2.6 billion in 2016 to pay in treatment costs covered by insurance…

Chris Lange | Apr 5, 2018 at 10:10 AM EDT

Conatus Pharmaceuticals Stumbles on Midstage Miss

Conatus Pharmaceuticals shares took a big step back on Thursday after the firm announced that its midstage proof-of-concept clinical trial…

Chris Lange | Apr 4, 2018 at 9:45 AM EDT

Proteostasis Therapeutics Wins Big With FDA Decision

Proteostasis Therapeutics shares made a solid gain on Wednesday after a key FDA decision was announced.

Chris Lange | Apr 3, 2018 at 9:45 AM EDT

Celgene Shuffles the Deck: COO Steps Down Immediately

Celgene is shuffling the deck in terms of its executive leadership, and one of its top executives is stepping down.

Chris Lange | Apr 3, 2018 at 8:50 AM EDT

Rigel Pharmaceuticals Stumbles on Midstage Kidney Trial

Rigel Pharmaceuticals saw its shares pull back early on Tuesday after the firm announced topline data from a midstage study.

1 … 137 138 139 140 141 … 392

Health and Healthcare Articles

All Health and Healthcare Articles

Selecta Biosciences Sinks Despite Positive Midstage Data

Why Spectrum Pharmaceuticals Is Climbing

Why Analysts See Pacira Pharma in a Night and Day Contrast

Surface Oncology Announces Potential Pricing for IPO

Therapix Takes a Big Step Forward With Its Cannabinoid Platform

Merck Moves Ahead With Late-Stage Trial Win

Why Menlo Therapeutics Shares Were Halved

Novartis Gambles $8.7 Billion on Gene-Therapy Firm

These 5 Stocks Could Be in Big Trouble If Interest Rates Go Higher

What Has Tanked Incyte and NewLink Genetics

What the Opioid Epidemic Costs Employers

Conatus Pharmaceuticals Stumbles on Midstage Miss

Proteostasis Therapeutics Wins Big With FDA Decision

Celgene Shuffles the Deck: COO Steps Down Immediately

Rigel Pharmaceuticals Stumbles on Midstage Kidney Trial

Wealthy, Rich, or Upper Class? The retirement numbers at every tier

Bernstein Analyst: AI Agents Drive Chip Demand ‘Off the Charts,’ Supply Can’t Keep Up

Eli Lilly Captures 60% of the GLP-1 Market as Mounjaro Revenue Soars 125%

A Couple With $3.1 Million Disagrees on Whether to Take Social Security at 62 or 70

This health insurer lost 2 million customers — and made $1.5 Billion anyway. Here's how

Wealthy, Rich, or Upper Class? The retirement numbers at every tier

Bernstein Analyst: AI Agents Drive Chip Demand ‘Off the Charts,’ Supply Can’t Keep Up

Health and Healthcare Articles

All Health and Healthcare Articles

Selecta Biosciences Sinks Despite Positive Midstage Data

Why Spectrum Pharmaceuticals Is Climbing

Why Analysts See Pacira Pharma in a Night and Day Contrast

Surface Oncology Announces Potential Pricing for IPO

Therapix Takes a Big Step Forward With Its Cannabinoid Platform

Merck Moves Ahead With Late-Stage Trial Win

Why Menlo Therapeutics Shares Were Halved

Novartis Gambles $8.7 Billion on Gene-Therapy Firm

These 5 Stocks Could Be in Big Trouble If Interest Rates Go Higher

What Has Tanked Incyte and NewLink Genetics

What the Opioid Epidemic Costs Employers

Conatus Pharmaceuticals Stumbles on Midstage Miss

Proteostasis Therapeutics Wins Big With FDA Decision

Celgene Shuffles the Deck: COO Steps Down Immediately

Rigel Pharmaceuticals Stumbles on Midstage Kidney Trial

Wealthy, Rich, or Upper Class? The retirement numbers at every tier

Bernstein Analyst: AI Agents Drive Chip Demand ‘Off the Charts,’ Supply Can’t Keep Up

Eli Lilly Captures 60% of the GLP-1 Market as Mounjaro Revenue Soars 125%

Featured Reads

A Couple With $3.1 Million Disagrees on Whether to Take Social Security at 62 or 70

This health insurer lost 2 million customers — and made $1.5 Billion anyway. Here's how